About the Authors

Gouri Yogalingam

Roles Data curation, Formal analysis, Investigation, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

gyogalingam@bmrn.com

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Amanda R. Luu

Roles Methodology

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Heather Prill

Roles Methodology

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Melanie J. Lo

Roles Methodology

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Bryan Yip

Roles Methodology

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

John Holtzinger

Roles Conceptualization, Methodology

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Terri Christianson

Roles Methodology, Supervision

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Mika Aoyagi-Scharber

Roles Conceptualization, Investigation, Project administration

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Roger Lawrence

Roles Supervision

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Brett E. Crawford

Roles Supervision

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Jonathan H. LeBowitz

Roles Conceptualization, Writing – review & editing

Affiliation Research, BioMarin Pharmaceutical, Inc., Novato, CA, United States of America

Competing Interests

All authors are full time employees of BioMarin Pharmaceutical Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Mika Aoyagi-Scharber, Terri M. Christianson and Jonathan H. LeBowitz, together with others, are inventors on a patent claiming compositions and methods for treating Sanfilippo type B, comprising therapeutic NAGLU-IGF2 fusion proteins (US 9,376,480 B2).